As such, the clinical context for application of such panel is not envisioned in cancer initial detection/screening, (where identification of the specific tumor type is obviously a requirement), but rather as an adjunct during disease monitoring, most likely in combination also with tumor-specific markers, as available (such as CA125, PSA, as described below). This evidence concerns the gene MUC16 and cancer.